For emerging and late-stage biotechs, out-licensing is often viewed as the safer path. Data from our five-year analysis of real-world licensing deal outcomes tells a different story.
In this paper, EVERSANA experts break down two critical decisions:
- Out-license vs. launch independently?
- If the former, at which stage will out-licensing maximize transactional value?
Our experts dive into the key launch and licensing paths that biotechs consider, revealing when commercialization becomes your strongest leverage for long-term value creation.
“Data consistently shows that companies launching and commercializing their own products achieve market capitalizations more than 6x higher than those that rely solely on licensing.”
Author
Farah Toublan, Ph.D., is an associate partner with the EVERSANA MANAGEMENT CONSULTING team. She is based in the New York City area.
Xavier is a Consultant at EVERSANA MANAGEMENT CONSULTING with applied and academic life science industry experience. Xavier has worked on a variety of engagements across the Market Access and Launch & Complete Commercialization practices,…
Mike is helping EVERSANA lead the way in end-to-end, integrated commercialization for the life sciences industry. He leverages more than 30 years of experience across pharma to drive EVERSANA COMPLETE Commercialization, the industry’s only…
Maneesh comes to EVERSANA Management Consulting from IQVIA. He held a number of leadership roles over his 10 years at the firm, most recently serving as Practice Lead, Launch Excellence and Brand and Commercial…
Faruk is a life sciences professional with extensive experience addressing a broad range of strategic issues, including corporate development, portfolio planning, and launch excellence.